Peter Attia's Blood Pressure Protocol Explained

A number with no feeling attached to it is easy to ignore. Blood pressure is exactly that kind of number. There is no ache, no fatigue, no warning sign that tells a person their arteries are under mechanical strain every time the heart beats. Physician Peter Attia calls this the central problem of the condition on this AMA rebroadcast.

High blood pressure is often referred to as a silent killer because it really doesn't have a warning sign. (Peter Attia, [38:12])

Everything else in the episode follows from that sentence. If the body will not tell someone their blood pressure is a problem, someone has to go find out, and then has to know what to do about it.

What the two numbers actually mean

Every blood pressure reading has two phases. The first is systole, when the heart's main pumping chamber, the left ventricle, squeezes and pushes blood out to the body. That produces the higher number. The second is diastole, when the heart relaxes and refills, and the pressure inside the arteries, though lower, never drops to zero (06:13). A reading of 120 over 80 describes those two moments in a single heartbeat.

Guidelines for what counts as normal changed in 2017, after a trial called SPRINT reshaped how doctors think about treatment (11:03). Under the current definitions, normal is under 120 systolic and under 80 diastolic. Elevated is 120 to 129 with diastolic still under 80. Stage one hypertension starts at 130 systolic or 80 diastolic. Stage two begins at 140 systolic or 90 diastolic (11:38). The SPRINT trial itself, published in 2015, randomized nearly 10,000 high cardiovascular risk adults without type 2 diabetes to a systolic target under 120 or a standard target under 140 (13:19). The intensive group's risk of the primary composite outcome fell by roughly 25 percent, and the trial was stopped early because the benefit was too large to justify continuing the standard-care arm (16:33). All-cause mortality fell too, by 27 percent, a result Attia says caught researchers off guard.

The reason a few points of blood pressure matter so much becomes clearer with a related figure: each 20 mmHg increase in systolic pressure is linked to a doubling in the risk of death from stroke, heart disease, or other vascular disease (29:17). Attia frames chronically elevated pressure as a mechanical injury, not a chemical one.

Compounding is insanely powerful when it comes to this type of biology, whether it be smoking, ApoB, or blood pressure. (Peter Attia, [20:57])

ApoB is the cholesterol-carrying particle behind atherosclerosis, and Attia draws a direct comparison: smoking chemically damages the endothelium, the thin layer of cells lining blood vessels, ApoB particles pass through that damaged lining, and high blood pressure physically batters it (21:20). Run that process for forty years instead of three, and the SPRINT numbers look conservative.

Nearly half the country is living inside that process. Roughly 46 percent of American adults meet the criteria for stage one or stage two hypertension (24:49), and prevalence climbs steadily with age, reaching past 80 percent among people 75 and older. Three organs take the brunt of it: the heart, the brain, and the kidneys. The kidneys are especially exposed. They weigh about one to two percent of body weight but receive 20 to 25 percent of cardiac output with every heartbeat (33:02), which makes their small blood vessels unusually vulnerable to pressure damage. Attia says he watches a marker called cystatin C, which he considers a better gauge of kidney function than the standard test, creatinine, because it catches decline in patients whose glomerular filtration rate, a measure of how well the kidneys filter blood, looks technically normal but is too low for their age (34:03). On the brain side, the SPRINT Mind sub-study found that intensive blood pressure lowering cut the relative risk of dementia by about 16 percent (35:03).

If you care about your brain, if you care about your heart, and if you care about your kidneys, you need low blood pressure. (Peter Attia, [35:27])

Measuring it right, and lowering it without a pill

Attia's frustration with office blood pressure readings runs through much of the conversation. He says he ignores his own office numbers because the conditions are wrong: he has usually just walked in, is not seated according to protocol, and may have the cuff placed incorrectly. His fix is to put the burden of accurate measurement on the patient.

Don't be lazy and check your blood pressure over your clothing. If you can't roll your sleeves all the way up, take your shirt off. (Peter Attia, [40:50])

The list of things that can distort a reading is long: a poorly fitted cuff, a cuff over clothing, an unsupported back, crossed legs (a five to eight mmHg swing), skipping the five-minute rest period (up to 10 to 20 mmHg), talking during the reading (10 to 15 points), being in pain (10 to 30 mmHg), and a full bladder, which alone can raise both heart rate and blood pressure by 10 to 15 points (39:17 to 42:19). Arm position matters too: every inch the arm sits above or below heart level shifts the reading by about 2 mmHg. Attia trusts manual readings, taken with a cuff and stethoscope, over automated cuffs, which he has found tend to run higher, though he admits he cannot fully explain why (46:46). His broader rule is that no single reading should drive a medical decision. He wants two to three checks a day for two weeks before deciding anything.

With ApoB you can't go too low. With blood pressure, you can go too low. (Peter Attia, [23:19])

That asymmetry, unlike a lipid marker where lower is simply better, is why Attia is cautious about medicating borderline numbers. About 10 percent of hypertension cases have a secondary cause, a correctable medical condition such as a tumor of the adrenal gland, kidney artery narrowing, or a thyroid problem (52:07). Attia recounts a friend whose blood pressure would not respond to medication until doctors found and removed a pheochromocytoma, a catecholamine-secreting adrenal tumor, after which his numbers normalized completely (54:15).

For the other 90 percent, the primary cases, Attia argues lifestyle change carries unusual weight.

Lifestyle is a far greater hammer on blood pressure than it is on lipids. (Peter Attia, [58:25])

Weight loss alone produces about one mmHg of systolic reduction per kilogram lost (59:50). Sodium is more contested: nephrologist Rick Johnson told Attia on a separate episode that drinking water with or before a salty meal blunts the pressure spike that follows, because thirst after salt signals the spike has already begun (61:08). Cutting sodium to extremes, as low as 1,500 milligrams a day against an average American intake of 3.5 to 4.5 grams, may lower blood pressure by five to six mmHg but is linked to higher all-cause mortality in recent meta-analysis, so Attia treats aggressive sodium restriction with caution (62:38). Exercise has cleaner data: 90 to 150 minutes a week of aerobic training at 65 to 75 percent of maximum heart rate, the zone Attia calls zone two, lowers systolic pressure by as much as eight mmHg. Resistance training adds a smaller effect, and isometric resistance training, holding a static contraction rather than lifting through a range of motion, produced the largest resistance-based drop his team found, about six mmHg systolic (63:15 to 64:36). Poor sleep matters as well: sleeping less than five hours a night is linked to a 40 percent higher risk of hypertension (67:11).

When lifestyle is not enough, four drug classes make up first-line treatment: thiazide diuretics, calcium channel blockers, ACE inhibitors, and ARBs. Attia's team ran an internal review and concluded ARBs edge out ACE inhibitors on side effects, mainly a lower rate of cough, while matching them on efficacy, though ACE inhibitors remain cheaper and more likely to be covered by insurance (68:08 to 70:20). In African American patients specifically, thiazide diuretics and calcium channel blockers appear to reduce cardiovascular events more effectively than ACE inhibitors, ARBs, or beta blockers (73:23).

What stays with a listener is not any single number but Attia's closing comment, that none of this is glamorous.

It's just bread and butter primary care medicine, but it's so needle moving. (Peter Attia, [75:09])

No senescent cells, no rapamycin, no biohacking story. Just a cuff, five quiet minutes, and the discipline to look at the number even though it never asks to be looked at.